GSK shares fall after blood cancer drug likely headed for U.S. rejection

• click to rate

  Posted by Two Blokes 9 hours ago - Filed in Stock - 0 views
  
  GSK shares fell more than 6% on Friday after a U.S. FDA advisory panel recommended against approving its blood cancer drug Blenrep, citing earlier concerns over eye-related side effects.